Update on the Treatment of Metastatic Urothelial Carcinoma

Nedal Bukhari, Humaid O Al-Shamsi, Faisal Azam, Nedal Bukhari, Humaid O Al-Shamsi, Faisal Azam

Abstract

Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years. Clinical trials are currently ongoing to determine how best to use and sequence these treatments. In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy. This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.

References

    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology. 2017;71(1):96–108. doi: 10.1016/j.eururo.2016.06.010.
    1. Bladder cancer risk factors. Bladder Cancer Risk Factors. .
    1. Bellmunt J., Petrylak D. P. New therapeutic challenges in advanced bladder cancer. Seminars in Oncology. 2012;39(5):598–607. doi: 10.1053/j.seminoncol.2012.08.007.
    1. Farina M. S., Lundgren K. T., Bellmunt J. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs. 2017;77(10):1077–1089. doi: 10.1007/s40265-017-0748-7.
    1. Loehrer P. J., Sr., Einhorn L. H., Elson P. J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. Journal of Clinical Oncology. 1992;10(7):1066–1073. doi: 10.1200/JCO.1992.10.7.1066.
    1. Sternberg C. N., de Mulder P. H. M., Schornagel J. H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european organization for research and treatment of cancer protocol no. 30924. Journal of Clinical Oncology. 2001;19(10):2638–2646. doi: 10.1200/JCO.2001.19.10.2638.
    1. Gabrilove J. L., Jakubowski A., Scher H., et al. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium. The New England Journal of Medicine. 1988;318(22):1414–1422. doi: 10.1056/NEJM198806023182202.
    1. von der Maase H., Hansen S. W., Roberts J. T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology. 2000;18(17):3068–3077. doi: 10.1200/JCO.2000.18.17.3068.
    1. Bellmunt J., von der Maase H., Mead G. M., et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. Journal of Clinical Oncology. 2012;30(10):1107–1113. doi: 10.1200/JCO.2011.38.6979.
    1. Sridhar S. S. Evolving treatment of advanced urothelial cancer. Journal of Oncology Practice. 2017;13(5):309–315. doi: 10.1200/JOP.2017.022137.
    1. Balar A. Urothelial Cancer. Journal of Clinical Oncology. 2017;35(19)
    1. Bellmunt J., Choueiri T. K., Fougeray R., et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. Journal of Clinical Oncology. 2010;28(11):1850–1855. doi: 10.1200/JCO.2009.25.4599.
    1. Galsky M. D., Hahn N. M., Rosenberg J., et al. Treatment of patients with metastatic urothelial cancer “Unfit” for cisplatin-based chemotherapy. Journal of Clinical Oncology. 2011;29(17):2432–2438. doi: 10.1200/JCO.2011.34.8433.
    1. De Santis M., Bellmunt J., Mead G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. Journal of Clinical Oncology. 2012;30(2):191–199. doi: 10.1200/JCO.2011.37.3571.
    1. Dogliotti L., Cartenì G., Siena S., et al. Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial. European Urology. 2007;52(1):134–141. doi: 10.1016/j.eururo.2006.12.029.
    1. Sternberg C. N., Calabrò F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92(12):2993–2998. doi: 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>;2-2. doi: 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>;2-2.
    1. Calabrò F., Lorusso V., Rosati G., et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652–2659. doi: 10.1002/cncr.24313.
    1. Dreicer R., Gustin D. M., See W. A., Williams R. D. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. The Journal of Urology. 1996;156(5):1606–1608. doi: 10.1016/S0022-5347(01)65459-4.
    1. Roth B. J., Dreicer R., Einhorn L. H., et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 1994;12(11):2264–2270. doi: 10.1200/JCO.1994.12.11.2264.
    1. De Wit R., Kruit W. H. J., Stoter G., De Boer M., Kerger J., Verweij J. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; Results of a phase II study in non-chemotherapy-pretreated patients. British Journal of Cancer. 1998;78(10):1342–1345. doi: 10.1038/bjc.1998.681.
    1. Moore M. J., Tannock I. F., Ernst D. S., Huan S., Murray N. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. Journal of Clinical Oncology. 1997;15(12):3441–3445. doi: 10.1200/JCO.1997.15.12.3441.
    1. O'Donnell P. H., Grivas P., Balar A. V., et al. Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab in cisplatin-ineligible advanced urothelial cancer (abstract 4502). Proceedings of the 2017 Annual meeting American Society of Clinical Oncology; 2017.
    1. Balar A. V., Galsky M. D., Rosenberg J. E., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389(10064):67–76. doi: 10.1016/S0140-6736(16)32455-2.
    1. Bellmunt J., de Wit R., Vaughn D. J., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. The New England Journal of Medicine. 2017;376(11):1015–1026. doi: 10.1056/NEJMoa1613683.
    1. Bladder Cancer Risk Factors. .
    1. Rosenberg J. E., Hoffman-Censits J., Powles T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. The Lancet. 2016;387(10031):1909–1920. doi: 10.1016/S0140-6736(16)00561-4.
    1. Bono P., Kim J. W., Spiliopoulou P., Calvo E., Pillai R. N. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. .
    1. Sharma P., Retz M., Siefker-Radtke A., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 2017;18(3):312–322. doi: 10.1016/S1470-2045(17)30065-7.
    1. Massard C., Gordon M. S., Sharma S., et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. Journal of Clinical Oncology. 2016;34(26):3119–3125. doi: 10.1200/JCO.2016.67.9761.
    1. Apolo A. B., Infante J. R., Balmanoukian A., et al. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study. Journal of Clinical Oncology. 2017 doi: 10.1200/JCO.2016.71.6795.
    1. A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Identifier NCT02603432
    1. Bellmunt J., Théodore C., Demkov T., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Journal of Clinical Oncology. 2009;27(27):4454–4461. doi: 10.1200/JCO.2008.20.5534.
    1. Ko Y.-J., Canil C. M., Mukherjee S. D., et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. The Lancet Oncology. 2013;14(8):769–776. doi: 10.1016/S1470-2045(13)70162-1.
    1. Sweeney C. J., Roth B. J., Kabbinavar F. F., et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of Clinical Oncology. 2006;24(21):3451–3457. doi: 10.1200/JCO.2005.03.6699.
    1. Mohammed A. A., EL-Tanni H., EL-Khatib H. M., Mirza A. A., Mirza A. A., Alturaifi T. H. Urinary bladder cancer: biomarkers and target therapy, new era for more attention. Oncology Reviews. 2016;10(2) doi: 10.4081/oncol.2016.320.
    1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Identifier: NCT02465060
    1. Petrylak D. P., Raymond P., Jingsong Z., et al. A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer. Proceedings of the 2017 ASCO annual meeting, abstract 106; Updated analysis of patients with metastatic urothelial cancer. Daniel Peter Petrylak;
    1. Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Identifier: NCT02853305
    1. Petrylak D., Chi K., Drakaki A., et al. LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Annals of Oncology. 2017;28(suppl_5) doi: 10.1093/annonc/mdx440.028.
    1. Identifier: NCT02516241. NCT02516241: 39 Identifier; Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer.
    1. Choi W., Ochoa A., McConkey D. J., et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. European Urology. 2017;72(3):354–365. doi: 10.1016/j.eururo.2017.03.010.
    1. Shah A. Y., Gao J., Siefker-Radtke A. O. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017;9(10):781–784. doi: 10.2217/imt-2017-0073.
    1. Zichi C., Tucci M., Leone G., et al. Immunotherapy for patients with advanced urothelial cancer: Current evidence and future perspectives. BioMed Research International. 2017;2017 doi: 10.1155/2017/5618174.5618174
    1. Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566. Identifier: NCT02315066
    1. Bartkowiak T., Curran M. A. 4-1BB agonists: multi-potent potentiators of tumor immunity. Frontiers in Oncology. 2015;5, article 117 doi: 10.3389/fonc.2015.00117.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren